RB regulates the stability and the apoptotic function of p53 via MDM2 - PubMed (original) (raw)
RB regulates the stability and the apoptotic function of p53 via MDM2
J K Hsieh et al. Mol Cell. 1999 Feb.
Free article
Abstract
The binding of RB to MDM2 is shown to be essential for RB to overcome both the antiapoptotic function of MDM2 and the MDM2-dependent degradation of p53. The RB-MDM2 interaction does not prevent MDM2 from inhibiting p53-dependent transcription, but the RB-MDM2 complex still binds to p53. Since RB specifically rescues the apoptotic function but not the transcriptional activity of p53 from negative regulation by MDM2, transactivation by wild-type p53 is not required for the apoptotic function of p53. However, an RB-MDM2-p53 trimeric complex is active in p53-mediated transrepression. These data link directly the function of two tumor suppressor proteins and demonstrate a novel role of RB in regulating the apoptotic function of p53.
Similar articles
- E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction.
Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X. Hsieh JK, et al. Genes Dev. 1997 Jul 15;11(14):1840-52. doi: 10.1101/gad.11.14.1840. Genes Dev. 1997. PMID: 9242491 - The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth.
Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K, Xiao ZX. Sdek P, et al. J Biol Chem. 2004 Dec 17;279(51):53317-22. doi: 10.1074/jbc.M406062200. Epub 2004 Oct 13. J Biol Chem. 2004. PMID: 15485814 - Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
Wunderlich M, Berberich SJ. Wunderlich M, et al. Oncogene. 2002 Jun 27;21(28):4414-21. doi: 10.1038/sj.onc.1205541. Oncogene. 2002. PMID: 12080472 - mdm2: a bridge over the two tumour suppressors, p53 and Rb.
Yap DB, Hsieh JK, Chan FS, Lu X. Yap DB, et al. Oncogene. 1999 Dec 13;18(53):7681-9. doi: 10.1038/sj.onc.1202954. Oncogene. 1999. PMID: 10618708 Review. - Regulation and activation of p53 and its family members.
Lohrum MA, Vousden KH. Lohrum MA, et al. Cell Death Differ. 1999 Dec;6(12):1162-8. doi: 10.1038/sj.cdd.4400625. Cell Death Differ. 1999. PMID: 10637431 Review.
Cited by
- Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53.
Liu Z, Yang Y, Sun X, Ma R, Zhang W, Wang W, Yang G, Wang H, Zhang J, Wang Y, Tian J. Liu Z, et al. Molecules. 2024 Feb 4;29(3):725. doi: 10.3390/molecules29030725. Molecules. 2024. PMID: 38338471 Free PMC article. - Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression.
Zhou Y, Nakajima R, Shirasawa M, Fikriyanti M, Zhao L, Iwanaga R, Bradford AP, Kurayoshi K, Araki K, Ohtani K. Zhou Y, et al. Biology (Basel). 2023 Dec 11;12(12):1511. doi: 10.3390/biology12121511. Biology (Basel). 2023. PMID: 38132337 Free PMC article. Review. - Genome homeostasis defects drive enlarged cells into senescence.
Manohar S, Estrada ME, Uliana F, Vuina K, Alvarez PM, de Bruin RAM, Neurohr GE. Manohar S, et al. Mol Cell. 2023 Nov 16;83(22):4032-4046.e6. doi: 10.1016/j.molcel.2023.10.018. Epub 2023 Nov 16. Mol Cell. 2023. PMID: 37977116 Free PMC article. - MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors.
Sun SY, Crago A. Sun SY, et al. J Clin Med. 2023 May 24;12(11):3638. doi: 10.3390/jcm12113638. J Clin Med. 2023. PMID: 37297833 Free PMC article. Review. - Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches.
Nguyen HM, Paulishak W, Oladejo M, Wood L. Nguyen HM, et al. Breast Cancer. 2023 Mar;30(2):167-186. doi: 10.1007/s12282-022-01415-4. Epub 2022 Nov 18. Breast Cancer. 2023. PMID: 36399321 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous